Effect of Early High-Dose Recombinant Human Erythropoietin on Behavior and Quality of Life in Children Aged 5 Years Born Very Preterm: Secondary Analysis of a Randomized Clinical Trial

IMPORTANCE: In light of the promising neuroprotective properties of recombinant human erythropoietin (RHEpo), the Swiss EPO Neuroprotection Trial was started to investigate its effect on neurodevelopment in very preterm infants. The results of the primary and secondary outcome analysis did not show...

Descripción completa

Detalles Bibliográficos
Autores principales: Picotti, Eleonora, Reinelt, Tilman, Koller, Brigitte, Bucher, Hans Ulrich, Rüegger, Christoph M., Fauchère, Jean-Claude, Natalucci, Giancarlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856490/
https://www.ncbi.nlm.nih.gov/pubmed/36477478
http://dx.doi.org/10.1001/jamanetworkopen.2022.45499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856490/
https://www.ncbi.nlm.nih.gov/pubmed/36477478
http://dx.doi.org/10.1001/jamanetworkopen.2022.45499

Ejemplares similares